|Bid||0.5050 x 1200|
|Ask||0.5900 x 800|
|Day's Range||0.5002 - 0.5893|
|52 Week Range||0.4200 - 4.9150|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.20|
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient advocacy conferences: American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting – May 16-19, 2022, Washington, D.C.Carl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will pr
One thing we could say about the analysts on Solid Biosciences Inc. ( NASDAQ:SLDB ) - they aren't optimistic, having...
Solid Biosciences Inc. is laying off about 35% of its workforce as it streamlines its manufacturing and R&D processes.